Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) on Thursday released topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study evaluating Xtandi ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

—These findings suggest that conventional imaging significantly underestimates the extent of disease in high-risk, biochemically recurrent prostate cancer, potentially impacting treatment decisions ...

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk ...

(RTTNews) - Pfizer Inc. (PFE) and Astellas Pharma U.S. Inc. announced final overall survival results from the Phase 3 EMBARK study evaluating XTANDI (enzalutamide), in combination with leuprolide and ...

Pfizer and Astellas are underlining the benefits of Xtandi as part of a combination therapy for certain patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with an overall survival ...

Sexual function data support enzalutamide as monotherapy and combined with leuprolide in patients with high-risk biochemically recurrent prostate cancer. Enzalutamide monotherapy maintains sexual ...

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...

Following the 2025 ESMO Congress, Dr. Joshua Saba sat down with Dr. Chandler Park to discuss recent advances in prostate cancer care. Following the 2025 European Society of Medical Oncology (ESMO) ...